While use of hormone-replacement therapy (HRT) effectively alleviates menopausal symptoms and prevents osteoporosis and possibly cardiovascular disease, there is concern of a detrimental impact on breast-cancer risk.
There is a particular lack of data regarding the effect of long-term use of oestrogen-progestin combinations on breast-cancer risk.
We conducted a large epidemiological study in Sweden, where combined oestrogen-progestin treatment has been predominant, to examine the influence of different regimens of menopausal hormone therapy on breast-cancer risk.
In this population-based case-control study, 3,345 women aged 50 to 74 years with invasive breast cancer (84% of all eligible) and 3,454 controls of similar age (82% of all selected) were included.
Mailed questionnaires and telephone interviews were used to collect detailed information on use of hormone replacement and on potential confounding factors.
Odds ratios (OR) and 95% confidence intervals (Cl) were estimated through multiple logistic regression.
There was a trend of increasing breast-cancer risk with duration of oestrogen/oestrogen-progestin use (OR for women treated at least 10 years, 2.43 ; 95% Cl, 1.79-3.30, as compared to never-users), with statistically significant estimates only for women with BMI<27 kg/m2.
Excess risks were observed to current use and use that ceased more than 10 years ago.
(OR for women treated at least 5 years, OR was 2.68,95% Cl, 2.09-3.42, and OR 2.57,95% Cl, 1.28-5. (...)
Mots-clés Pascal : Tumeur maligne, Glande mammaire, Traitement substitutif, Oestrogène, Progestérone, Hormone stéroïde, Long terme, Facteur risque, Epidémiologie, Etude cas témoin, Suède, Europe, Homme, Glande mammaire pathologie
Mots-clés Pascal anglais : Malignant tumor, Mammary gland, Replacement therapy, Estrogen, Progesterone, Steroid hormone, Long term, Risk factor, Epidemiology, Case control study, Sweden, Europe, Human, Mammary gland diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0214532
Code Inist : 002B20E02. Création : 16/11/1999.